ArticleJournal of cardiovascular imaging2026
Effect of empagliflozin with or without carvedilol on tricuspid regurgitation and right ventricular remodeling: PROVE trial.
Article in Journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04345796 (Multicenter, Randomized, 2 x 2 Factorial, Phase 3 Study to Assess the Efficacy of Carvedilol and Empagliflozin on Improvement of Right Ventricular Remodeling in Patients With Severe Functional Tricuspid Regurgitation), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter, Randomized, 2 x 2 Factorial, Phase 3 Study to Assess the Efficacy of Carvedilol and Empagliflozin on Improvement of Right Ventricular Remodeling in Patients With Severe Functional Tricuspid Regurgitation
Who cites it
1 citing paper in PubMed.
- Less regurgitation without reverse remodeling: what the PROVE trial teaches us about functional tricuspid regurgitation.Journal of cardiovascular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional tricuspid regurgitation (TR) is associated with adverse outcomes. As TR, right ventricular (RV) remodeling, and worsening TR form a vicious cycle, therapies that reverse RV remodeling and reduce TR are needed. We examined whether sustained-release carvedilol (carvedilol SR), empagliflozin, or their combination reduces RV volumes and TR severity in patients with significant functional TR.
methodsIn this randomized trial with a 2 × 2 factorial design, 56 patients were assigned to carvedilol SR plus empagliflozin, carvedilol SR, empagliflozin, or placebo. The primary end point was the change in RV end-systolic volume index from baseline to 12 months. Secondary end points included changes in RV end-diastolic volume index, RV ejection fraction, vena contracta width (VCW), effective regurgitant orifice area (EROA), and regurgitant volume. Cardiac magnetic resonance imaging assessed RV volumes, and echocardiography evaluated TR severity.
resultsBaseline characteristics were well balanced between treatment groups (mean age 71 ± 7 years; men 55%; diabetes 14%; atrial fibrillation 89%). Empagliflozin did not change RV volumes or RV ejection fraction. However, empagliflozin reduced VCW (1.45 mm; 95% confidence interval [CI], 0.69-2.20), EROA (0.09 cm
conclusionsCarvedilol SR, empagliflozin, or their combination showed no significant reduction in RV volumes, but empagliflozin significantly reduced TR severity in patients with functional TR.
trial registrationClinicalTrials.gov identifier: NCT04345796 (PROVE trial).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.